Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Screening Blood Supply for Murine Viruses Is Superfluous

By LabMedica International staff writers
Posted on 11 Oct 2011
The validity of testing techniques intended to detect the presence of several viruses in blood donated for transfusion has been examined. More...


Murine leukemia viruses (MLV), including xenotropic-MLV-related virus (XMRV), and the related polytrophic murine leukemia viruses (P-MLVs) were looked for in blood samples of healthy donors who were previously known to not have the viruses.

In a recent study, blood samples were taken from healthy donors and from 14 patients with chronic fatigue syndrome (CFS) who had previously tested positive for XMRV or P-MLV, and samples from another person who had tested positive for XMRV but who did not have CFS. The study also used blood samples from healthy volunteers whose blood tests previously had shown no signs of XMRV/P-MLV. The scientists used 11 nucleic acid, five antibody, and three culture assays to determine the assays’ abilities to detect XMRV/P-MLVs. The study also checked for evidence of contamination with mouse DNA, because XMRV or its predecessors may be present in some mouse strains and cell lines. The MLV have been controversially linked to CFS.

The samples were blinded with no indication as to their source, and sent to nine laboratories. The study involved laboratories supported by several US governmental agencies along with Abbott Laboratories (Abbott Park, IL, USA), GenProbe, Inc. (San Diego, CA, USA), and the Whittemore Peterson Institute (WPI; Reno, NV, USA). The laboratories reported similar rates of finding XMRV in samples from patients with chronic fatigue syndrome and from healthy donors who were known to not have XMRV. Additional tests run in the same and other laboratories on the same samples did not find XMRV, strongly suggesting that these persons were negative for XMRV/P-MLVs. This would be a sign that the few observed positive results represented false-positives, which means the results indicated the condition was present when it actually was not.

Susan B. Shurin, MD, from the US National Institutes of Health (Bethesda, MD, USA), said, “The results of this study, along with other recent findings, reassure us that these viruses do not pose a threat to the safety of the nation’s blood supply. These data add to the mounting evidence that there is no need to screen blood donors for them at the present time.”

The report was published on September 22, 2011, in the journal Science Express.

Related Links:
Abbott Laboratories
GenProbe
US National Institutes of Health


Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
Alcohol Testing Device
Dräger Alcotest 7000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.